Adagio Medical Holdings, Inc. (ADGM)
NASDAQ: ADGM · Real-Time Price · USD
1.250
+0.080 (6.84%)
At close: Apr 2, 2026, 4:00 PM EDT
1.230
-0.020 (-1.60%)
After-hours: Apr 2, 2026, 4:22 PM EDT
Company Description
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias.
It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia.
The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories.
Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.
Adagio Medical Holdings, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 80 |
| CEO | Todd Usen |
Contact Details
Address: 26051 Merit Circle, Suite 102 Laguna Hills, California 92653 United States | |
| Phone | 949 348 1188 |
| Website | adagiomedical.com |
Stock Details
| Ticker Symbol | ADGM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2006986 |
| CUSIP Number | 00534B100 |
| ISIN Number | US00534B1008 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Todd Usen | Chief Executive Officer and Director |
| Deborah Kaster | Chief Financial Officer and Chief Business Officer |
| Antwan Gipson M.B.A. | Senior Vice President of Manufacturing and Operations |
| Dr. Alex Babkin Ph.D. | Chief Technical Officer |
| Nabil Jubran | Chief Compliance Officer |
| Ilya Grigorov | Vice President of Global Marketing and Product Management |
| Marie-Claude Jacques | Senior Vice President of Global Sales |
| Maryline Cullen | Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 2, 2026 | POS AM | Post-Effective amendments for registration statement |
| Apr 2, 2026 | POS AM | Post-Effective amendments for registration statement |
| Apr 1, 2026 | POS AM | Post-Effective amendments for registration statement |
| Apr 1, 2026 | POS AM | Post-Effective amendments for registration statement |
| Mar 30, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 27, 2026 | 424B3 | Prospectus |
| Mar 27, 2026 | 424B3 | Prospectus |
| Mar 27, 2026 | 10-K | Annual Report |
| Mar 27, 2026 | 8-K | Current Report |